Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

A phase III, double ­blind, randomized placebo controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The dal-­GenE trial

Clinical Trial Details

The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality (cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction (MI) and non-fatal stroke) in subjects with a documented recent acute coronary syndrome and the AA genotype in the ADCY9 gene. 

Key Eligibility: 

- Subjects with the appropriate genetic background and recently hospitalized for ACS (between 1 and 3 months). 

- Male and female subjects age 45 years and over at Visit 1. 

- AA genotype variant in the ADCY9 gene. 

Detailed eligibility discussed when you contact the study team.

Study contact by location

Upper East Side - Manhattan

Contact(s)

Kara Greenblatt
646-962-6038
kag2030@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

1606017336

Status

Open to Enrollment